GFM
CRSP icon

GF Fund Management’s CRISPR Therapeutics CRSP Stock Holding History

GF Fund Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
2,032
-108
-5% -$5.69K ﹤0.01% 323
2026
Q1 		$102K Buy
2,140
+268
+14% +$14.1K ﹤0.01% 339
2025
Q4 		$98.2K Sell
1,872
-2,767
-60% -$166K ﹤0.01% 343
2025
Q3 		$301K Buy
4,639
+1,238
+36% +$71.1K 0.01% 254
2025
Q2 		$165K Buy
3,401
+1,215
+56% +$47K ﹤0.01% 333
2025
Q1 		$74.4K Buy
2,186
+394
+22% +$16.7K ﹤0.01% 385
2024
Q4 		$70.5K Buy
+1,792
New +$84.6K ﹤0.01% 360

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GF Fund Management's CRSP Position: Q2 2026 in Review

GF Fund Management reduced its CRISPR Therapeutics (CRSP) stake by 5% in Q2 2026, selling an estimated $5.69K and leaving 2,032 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #323.

GF Fund Management first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $301K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • GF Fund Management held 2,032 shares of CRISPR Therapeutics worth $111K as of Q2 2026.
  • GF Fund Management sold 108 CRISPR Therapeutics shares in Q2 2026, an estimated $5.69K.
  • CRISPR Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #323 holding.
  • GF Fund Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's CRISPR Therapeutics position peaked at $301K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.